CSBio CSBio

X
[{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Presents Positive Phase 2a Data With SOM3355 at the 34thECNP Congress 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"SOM Biotech"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Granted Orphan Drug Designation by the FDA for SOM3355","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"SOM Biotech"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minoryx Therapeutics Doses First Patient With Leriglitazone In Registration-Enabling Cald Nexus Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Minoryx Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SOM3355 has potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease.

            Lead Product(s): SOM3355

            Therapeutic Area: Genetic Disease Product Name: SOM3355

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of chorea movements associated with Huntington’s disease (HD).

            Lead Product(s): SOM3355

            Therapeutic Area: Genetic Disease Product Name: SOM3355

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Phase 2 NEXUS trial aims at evaluating the safety and efficacy of leriglitazone in pediatric patients with early-stage cerebral ALD (cALD), the acute form of X-linked adrenoleukodystrophy (X-ALD).

            Lead Product(s): Leriglitazone

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY